Hong Kong Subsidizes Leukaemia Drug, Reducing Patient Costs

Hongkongers to pay only HK$240 a year for leukaemia drug after system shake-up

More than 400 cancer patients are set to benefit from Hong Kong health authorities’ decision to subsidise a leukaemia drug, and will go from paying up to HK$500,000 (US$63,800) a year for treatment to forking out just HK$240. The Hospital Authority said on Wednesday that it began subsidising the medication, Dasatinib, in April, with the government expected to set aside an additional HK$49 million in annual spending to help cover the cost. As part of the move, Dasatinib was reclassified from a...

By Theodora Yu